PRISM NextGen Tech Stocks Soundhound AI (SOUN) and Recursion Pharmaceuticals (RXRX) See Share Prices Soar From Nvidia Disclosure
    PRISM NextGen Tech Stocks Soundhound AI (SOUN) and Recursion Pharmaceuticals (RXRX) See Share Prices Soar From Nvidia Disclosure
    PRISM Daily

    February 15, 2024 - by Greg Barton

    PRISM NextGen Tech Stocks Soundhound AI (SOUN) and Recursion Pharmaceuticals (RXRX) See Share Prices Soar From Nvidia Disclosure

    15 February 2024

    New York, February 15, 2024 - PRISM MarketView - Today the megacap AI chipmaker Nvidia (NVDA) disclosed its stake in some smaller AI firms that has boosted shares for those associated with the disclosure.
    PRISM NextGen Tech stock Soundhound AI, Inc. (SOUN) rose by 73% upon Nvidia announcing its $3.7M investment in the conversational voice assistant developer while TechBio company Recursion Pharmaceuticals, Inc. (RXRX) is up 15% from Nvidia’s $76M investment.

    NextGen Stock Prices at Prism MarketView

    Technology continues to evolve as Artificial Intelligence becomes more prominent. The “next-gen wave” has contributed to additional technological advances s

    Read More

    SoundHound AI, Inc. - Prism MarketView

    SoundHound AI, Inc. - Prism MarketView

    SoundHound’s independent voice AI platform connects people to brands through customized conversational experiences that voice-enable products, services, and a

    Read More

    Recursion Pharmaceuticals, Inc. - Prism MarketView

    Recursion Pharmaceuticals, Inc. - Prism MarketView

    Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the

    Read More

    Other names who also saw positive share movements that were included in the disclosure were med device company Nano-X (NNOX), autonomous driving tech company TuSimple Holdings (TSPH), and chip designer, Arm Holdings (ARM).
    PRISM MarketView does not provide investment advice.
    Media Contact
    Company Name: Prism MarketView
    Email: info@prismmarketview.com
    Phone: 646-863-6341
    Website: https://prismmarketview.com
    To see this content properly accept cookies.
    PRISM MarketView Social Media
    To see this content properly accept cookies.
    To see this content properly accept cookies.
    Related Stories
    PRISM Daily
    Village Farms Breaks Ground on Indoor Cannabis Production Facility in the Netherlands

    New York, February 15, 2024 - PRISM MarketView - Village Farms International (Nasdaq: VFF) has begun construction on  its first indoor cannabis production facility in Drachten, Netherlands. The company plans to fund the build-out of the facility from cash on hand.

    15 February 2024

    PRISM Biotech
    Revolutionizing Drug Development: How AI Shortens the Journey from Lab to Lives

    New York, February 16, 2024 - PRISM MarketView - The journey of progressing a drug molecule from concept to commercialization is a lengthy and intricate process, typically spanning 10-15 years. This period encompasses the initial discovery phase, through to clinical tria...

    16 February 2024

    PRISM Biotech
    Greenwich LifeSciences Provides Update on Phase III Clinical Trial for Breast Cancer Immunotherapy; Shares Surge

    New York, February 15, 2024 - PRISM MarketView - Greenwich LifeSciences, Inc. (Nasdaq: GLSI), a clinical-stage biopharmaceutical company, provided an update on its Phase III clinical trial, Flamingo-01, focusing on GLSI-100, an immunotherapy aimed at preventing breast ca...

    15 February 2024

    PRISM Daily
    Clever Leaves Gains Exclusive License to Cultivate High Performance Cannabis

    New York, February 15, 2024 - PRISM MarketView - As part of its partnership with award-winning Dutch seed bank, Paradise Seeds, global medicinal cannabis company, Clever Leaves Holdings (Nasdaq: CLVR), will develop and register high performance cannabis cultivars in Colo...

    15 February 2024

    We use cookies to run our website, analyze your use of our services, manage your online preference & personalize ad content. By accepting our cookies, you’ll get relevant content and social media features, personalized ads, and an enhanced browsing experience. To manage your choices, click „Cookie Settings”. Necessary cookies are required for the core website functionality and cannot be rejected. For more information, see our Cookie Policy.
    Cookie settings
    Cookies used on the site are categorized and below you can read about each category and allow or deny some or all of them, except for Necessary Cookies which are required to provide core website functionality. When categories that have been previously allowed are disabled, all cookies assigned to that category will be removed from your browser. You can see a list of cookies assigned to each category and detailed information on those cookies in the “Cookie Policy” tab.
    Necessary cookies
    Some cookies are required to provide core functionality. The website won't function properly without these cookies and they are enabled by default and cannot be disabled.
    Preferences
    Preference cookies enables the website to remember information to customize how the website looks or behaves for each user. This may include storing selected currency region, language or color theme.
    Analytical cookies
    Analytical cookies help us improve our website by collecting and reporting information on its usage.
    Marketing cookies
    Marketing cookies are used to track visitors across websites to allow publishers to display relevant and engaging advertisements. By enabling marketing cookies, you grant permission for personalized advertising across various platforms.